A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Dr. Kelly Stratton answers the most frequently asked questions in prostate cancer regarding risk for recurrence, progression and treatment options. Navigating a prostate cancer diagnosis involves ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Many patients with high-risk biochemically recurrent prostate cancer based on PSA doubling time are unidentified in clinical practice. Clinicians unaware of patients’ PSA doubling time (PSADT) at ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...